Inorganic Chemistry · 2012 · 55 citations · 30 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCoordination ChemistryHeterocyclic ChemistryLigand BindingCell Motility AnalysisCell Motility ModelsCell Motility ModulationElectrophoretic MobilityGel ElectrophoresisPlatinum CompoundsPlatinum-based AgentsTumor Cell Motility
Hetero-multinuclear, platinum/ruthenium species were synthesized and tested for their effect on the motility of A549 (nonsmall cell lung) and MDA-MB-231 (breast) cancer cells and for their ability to inhibit DNA mobility using gel electrophoresis. It was found that the Ru(2)Pt trinuclear species [Na(2)]{[Ru(III)Cl(4)(DMSO-S)(-μ-pyz)](2)Pt(II)Cl(2)}, AH197, was much more efficient at inhibiting cell motility than [C(3)N(2)H(5)][Ru(III)Cl(4)(DMSO-S)(C(3)N(2)H(4))], NAMI-A, while the dinuclear RuPt species [K][Ru(III)Cl(4)(DMSO-S)(-μ-pyz)Pt(II)(DMSO-S)Cl(2)], IT127, was slightly better than NAMI-A. However, the dinuclear species retarded the electrophoretic mobility of DNA greater than both the trinuclear complex and cisplatin. The metal complexes and their respective BSA protein/metal adducts were studied by X-ray absorption spectroscopy. The spectra led to the conclusion that BSA donor atoms have substituted for the chloride ligands and perhaps the DMSO ligands.
30
Ruthenium metallopharmaceuticals
Michael J. Clarke · Coordination Chemistry Reviews · 2003 · 675 citations
Cell Migration and Invasion Assays as Tools for Drug Discovery
Keren I. Hulkower, Renee L. Herber · Pharmaceutics · 2011 · 396 citations · Full text